Biora Therapeutics, Inc. (NASDAQ:BIOR) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Chuck Padala – Managing Director, LifeSci Advisors Adi Mohanty – Chief Executive Officer Eric d’Esparbes – Chief Financial Officer Conference Call Participants Julian Harrison – BTIG Sahil Kazmi – B. Riley Securities Operator Welcome to the Biora Therapeutics First Quarter 2022 Earnings Call. During the presentation, all participants will be in a listen-only mode. Afterwards, we’ll conduct a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39334 Biora Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3950390 (State or other jurisdiction of ...

progenity® © 2022 Progenity, Inc. All rights reserved. CORPORATE PRESENTATION March 2022 FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this presentation, including statements concerning our plans, objectives, goals, strategies, future events, ...

Progenity, Inc. (PROG) Q4 2021 Earnings Conference Call March 28, 2022 4:30 PM ET Company Participants Chuck Padala - Managing Director of LifeSci Advisors Adi Mohanty - Chief Executive Officer Eric d'Esparbes - Chief Financial Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co, LLC Catherine Schulte - Robert W. Baird & Co. Inc. Operator Greetings, and welcome to the Progenity Fourth Quarter and Full-Year 2021 Earnings Call. At this time, all participants are in a listen-only mode. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39334 PROGENITY, INC. (Exact name of Registrant as specified in its Charter) Delaware 27-3950390 (State or other jurisdiction of inco ...

CORPORATE PRESENTATION November 2021 FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this presentation, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, plans or intentions ...

THIRD QUARTER 2021 – FINANCIAL RESULTS November 2021 FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this presentation, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, fin ...

Financial Data and Key Metrics Changes - The company generated $9.6 million in revenues during Q3 2021, with $9.4 million from discontinued operations, indicating a shift away from molecular testing operations [21] - Operating expenses, excluding stock-based compensation, were $32.7 million in Q3 2021, representing a $9 million favorable variance compared to previous guidance [22] - The company achieved a $110 million annual operating expenses run rate reduction during Q3 2021, with expectations to reach less than $25 million in Q4 [20][22] Business Line Data and Key Metrics Changes - The Oral Biotherapeutics program targets a $250 billion global biologics market, focusing on oral delivery of biomolecules [9] - The Drug Delivery System (DDS) program aims to treat GI localized diseases, initially targeting the $15 billion IBD market with lead drugs PGN-600 and PGN-001 [14] - The Preecludia test for preeclampsia demonstrated strong performance in validation studies, with potential for significant market impact [18][19] Market Data and Key Metrics Changes - The company is focusing on the biotherapeutics market, particularly oral delivery solutions and treatments for inflammatory bowel disease [26] - The Preecludia test has the potential to capture a share of the approximately $3 billion market in the U.S. [26] Company Strategy and Development Direction - The company is transforming into an innovation-led biotherapeutics company, focusing on oral delivery of biomolecules and GI IBD platforms [7][26] - There is a clear focus on advancing the pipeline, generating value from unique assets, and exploring partnerships [6][26] - The company aims to reduce cash burn and optimize capital allocation towards innovation [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the transformation process and the potential for the company's innovation pipeline to create value [26] - The company is focused on generating compelling data in the near term to de-risk its programs and enhance value [34] Other Important Information - The company raised $40 million in gross proceeds during Q3 2021 and had a cash balance of $54 million at the end of the quarter [24] - A proactive approach to managing capital structure has led to a 38% reduction in the balance of convertible notes [25] Q&A Session Summary Question: Update on Preecludia strategy and licensing opportunities - Management indicated that outreach to potential licensees for Preecludia is in the initial phase, with positive data supporting its value [28][29] Question: Details on the third pharma partnership for OBDS - Management stated that it is still early to provide detailed information on the partnership, emphasizing the importance of generated data [31] Question: Expectations for upcoming PK/PD data in UC and future clinical trials - Management noted that more data will be generated soon, which will help define necessary studies, and emphasized the unique nature of their drug development approach [34]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39334 Progenity, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3950390 (State or other jurisdiction of incor ...

/ ® CORPORATE PRESENTATION September 2021 FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this presentation, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "ob ...